Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes.
Following an update from the company (Novo Nordisk), NICE have suspended this appraisal from its current work programme until further notice. NICE will continue to monitor the situation and will provide an update when further information becomes available.
 
Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6175

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol

Stakeholders

Companies sponsors Novo Nordisk (insulin icodec)
Others Department of Health and Social Care
  NHS England
Patient carer groups None
Professional groups Royal College of Physicians
  UK Clinical Pharmacy Association
Associated public health groups None
Comparator companies A. Menarini Farmaceutica Internazionale (canagliflozin, metformin) (confidentiality agreement not signed, not participating)
  AstraZeneca (exenatide, dapagliflozin, metformin, saxagliptin) (confidentiality agreement signed, participating)
  Aurobindo Pharma (gliclazide, metformin, sitagliptin, vildagliptin) (confidentiality agreement not signed, not participating)
  Bioproject (glibenclamide) (confidentiality agreement not signed, not participating)
  Boehringer Ingelheim (empagliflozin, linagliptin, metformin) (confidentiality agreement not signed, not participating)
  Bristol laboratories (gliclazide) (confidentiality agreement not signed, not participating)
  Brown and Burk UK (gliclazide, glimepiride, metformin, pioglitazone) (confidentiality agreement not signed, not participating)
  Celix Pharma (metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Colonis Pharma (metformin) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Eli Lilly (dulaglutide, insulin, tirzepatide) (confidentiality agreement signed, participating)
  Flamingo Pharma (gliclazide) (confidentiality agreement not signed, not participating)
  Genus Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Ipca Laboratories (metformin) (confidentiality agreement not signed, not participating)
  Krka UK (gliclazide, sitagliptin) (confidentiality agreement not signed, not participating)
  Lupin Healthcare (gliclazide) (confidentiality agreement not signed, not participating)
  Morningside Healthcare (metformin) (confidentiality agreement not signed, not participating)
  MSD (ertugliflozin, metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Mylan (gliclazide, insulin, pioglitazone, sitagliptin) (confidentiality agreement not signed, not participating)
  Neon Healthcare (metformin, pioglitazone) (confidentiality agreement not signed, not participating)
  Novartis (metformin, vildagliptin) (confidentiality agreement not signed, not participating)
  Novo Nordisk (insulin, liraglutide, semaglutide) (confidentiality agreement not signed, not participating)
  Pfizer (glipizide) (confidentiality agreement not signed, not participating)
  Pinewood Healthcare (metformin) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (metformin) (confidentiality agreement not signed, not participating)
  Sandoz (metformin, pioglitazone) (confidentiality agreement not signed, not participating)
  Sanofi (insulin, lixisenatide) (confidentiality agreement not signed, not participating)
  Servier Laboratories (gliclazide) (confidentiality agreement not signed, not participating)
  Sigma Pharmaceuticals (metformin) (confidentiality agreement not signed, not participating)
  Sovereign Medical (tolbutamide) (confidentiality agreement not signed, not participating)
  Strides Pharma (metformin) (confidentiality agreement not signed, not participating)
  Sun Pharmaceuticals (sitagliptin) (confidentiality agreement not signed, not participating)
  Takeda (alogliptin, metformin) (confidentiality agreement not signed, not participating)
  Thame Laboratories (metformin, sitagliptin) (confidentiality agreement not signed, not participating)
  Tillomed Laboratories (metformin) (confidentiality agreement not signed, not participating)
  Wockhardt (metformin) (confidentiality agreement not signed, not participating)
  Zentiva (gliclazide, metformin, sitagliptin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
31 October 2024 Suspended. Following an update from the company (Novo Nordisk), NICE have suspended this appraisal from its current work programme until further notice. NICE will continue to monitor the situation and will provide an update when further information becomes available.
31 July 2024 Invitation to participate
04 June 2024 - 02 July 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6175
04 June 2024 In progress. Scoping commencing
31 August 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual